Free shipping on all orders over $ 500

Elesclomol

Cat. No. M2083
Elesclomol Structure
Synonym:

STA-4783

Size Price Availability Quantity
10mg USD 216 In stock
50mg USD 650 In stock
Bulk Inquiry?

Quality Control
Biological Activity

Elesclomol (STA-4783) is a first-in-class investigational compound currently undergoing clinical evaluation as a novel cancer therapeutic. Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7 and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. Elesclomol induces oxidative stress by provoking a buildup of reactive oxygen species within cancer cells. Elesclomol interacts with the electron transport chain (ETC) to generate high levels of ROS within the organelle and consequently cell death. Elesclomol induces apoptosis in cancer cells through the induction of oxidative stress. Treatment of cancer cells in vitro with elesclomol resulted in the rapid generation of reactive oxygen species (ROS) and the induction of a transcriptional gene profile characteristic of an oxidative stress response. In addition, N-acetylcysteine blocked drug-induced apoptosis, indicating that ROS generation is the primary mechanism responsible for the proapoptotic activity of elesclomol.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 400.52
Formula C19H20N4O2S2
CAS Number 488832-69-5
Purity 98.83%
Solubility DMSO 80 mg/mL
Storage at -20°C
References

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.
Blackman RK, et al. PLoS One. 2012;7(1):e29798. PMID: 22253786.

Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Qu Y, et al. Breast Cancer Res Treat. 2010 Jun;121(2):311-21. PMID: 19609669.

Elesclomol induces cancer cell apoptosis through oxidative stress.
Kirshner JR, et al. Mol Cancer Ther. 2008 Aug;7(8):2319-27. PMID: 18723479.

Related HSP90 Products
Teprenone

Teprenone(Geranylgeranylacetone; GGA)is commonly utilized to protect the gastric mucosa in peptic ulcer disease; has been shown to protect the myocardium from ischemia/reperfusion by activating heat shock proteins.

Celastrol

Celastrol is a potent antioxidant and anti-inflammatory agent and a novel HSP90 inhibitor.

CH5138303

CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.

Retaspimycin

Retaspimycin is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90).

KW-2478

KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Elesclomol, STA-4783 supplier, HSP90, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.